Quick Answer
Onconetix, Inc. reported Diluted EPS of $16.56 per share (loss) for fiscal year 2025.
Onconetix, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$16.56 | +99.1% |
| 2024 | -$1823.39 | -1985.1% |
| 2023 | -$87.45 | -7850.0% |
| 2022 | -$1.10 | +12.7% |
| 2021 | -$1.26 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.25 | +97.5% | -31.3% |
| June 30, 2025 | -$4.76 | +99.8% | -798.1% |
| March 31, 2025 | -$0.53 | +97.4% | +99.8% |
| September 30, 2024 | -$249.08 | -1940.0% | +88.6% |
| June 30, 2024 | -$2191.59 | -509572.1% | -10814.3% |
| March 31, 2024 | -$20.08 | -11055.6% | -64.5% |
| September 30, 2023 | -$12.21 | -4422.2% | -2739.5% |
| June 30, 2023 | -$0.43 | -19.4% | -138.9% |
- Onconetix, Inc. showed an increase of +99.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Onconetix, Inc.’s diluted eps has declined by 1214.3% (from $1.26 per share (loss) to $16.56 per share (loss)).
- The most recent figure is from Onconetix, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: